CORDIS provides links to public deliverables and publications of HORIZON projects.
Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .
Deliverables
This will include additional information obtained through deliverables D4.1. The study sites will adapt the generic influenza protocol by describing the study design(s), the outcomes, the settings (GP, hospital based), the types of vaccines, the plan of analysis, the variables that will be included in the analysis and how these are obtained, how previous vaccinations are accounted for etc. The plan of analysis will describe how to measure vaccine effectiveness (direct effect) in the elderly population, including adjustment for confounders by covariates or (if possible) imputations.
First season Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness. (opens in new window)Each season, the study sites will adapt the generic protocol by describing the setting in each of the seasons (e.g. vaccines used, start of vaccination campaign, change in the number of GPs participating in the surveillance network, etc).
Third Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness. (opens in new window)This will include additional information obtained through deliverables D4.1. The study sites will adapt the generic influenza protocol by describing the study design(s), the outcomes, the settings (GP, hospital based), the types of vaccines, the plan of analysis, the variables that will be included in the analysis and how these are obtained, how previous vaccinations are accounted for etc. The plan of analysis will describe how to measure vaccine effectiveness (direct effect) in the elderly population, including adjustment for confounders by covariates or (if possible) imputations.
Second Scientific communication: one article submitted or results from I-MOVE+ influenza vaccines presented in an International Scientific Conference. (opens in new window)At least one scientific article presenting the results of the influenza VE and impact I-MOVE+ studies will be submitted at the end of the season to an open source journal. An abstract will be submitted to the ESCAIDE conference or to any other relevant conference. (Month 18, Month 30, Month 40)
One manuscript submitted for publication and/or abstracts for at least one conference. (opens in new window)Studies results will be prepared for publication/presentations. At least one manuscript and at least one abstract will be prepared and submitted to relevant journals and conferences.
Generic protocol to measure impact of the seasonal influenza vaccine (opens in new window)The generic protocol will include the different settings and the populations to be compared to assess the different impact effects.
Second End of season, pooled influenza vaccine effectiveness estimates report. (opens in new window)The final pooled VE report will include the results of the multicentre case control studies (primary care and hospital studies) and a summary of the studies conducted within WP4 using electronic databases. The report will include the results of the research questions addressed (effect of previous vaccinations, duration of protection).
Submission of article summarising the I-MOVE+ experience in evaluating the influenza vaccines, results and perspective for the future. (opens in new window)At the end of the three year project, a summary article will be written summarising all the lessons learnt, the results of the research questions addressed (effect of previous vaccinations, duration of protection).
First Report I-Move+ ST/Scientific Meetings (opens in new window)Report I-MOVE+ ST/Scientific Meetings
Third Scientific communication: one article submitted or results from I-MOVE+ influenza vaccines presented in an International Scientific Conference. (opens in new window)At least one scientific article presenting the results of the influenza VE and impact I-MOVE+ studies will be submitted at the end of the season to an open source journal. An abstract will be submitted to the ESCAIDE conference or to any other relevant conference.
Generic protocols to measure influenza vaccine effectiveness at primary care and hospital level, using a test-negative design and screening method. (opens in new window)The generic protocols will include a description of the study design, the setting(s), the plan of analysis for study site estimates and for pooled estimates, the minimum set of variables to be collected, the sample size. They will specify the parts that each study site will have to document when writing the study site protocol. The generic protocols will detail the methods used and the plan of analysis to answer to specific research questions such as the effect of previous vaccinations and the duration of protection).
First Scientific communication: one article submitted or results from I-MOVE+ influenza vaccines presented in an International Scientific Conference. (opens in new window)At least one scientific article presenting the results of the influenza VE and impact I-MOVE+ studies will be submitted at the end of the season to an open source journal. An abstract will be submitted to the ESCAIDE conference or to any other relevant conference.
Report on influenza vaccine effectiveness and role of influenza on IPD and/or CAP incidence (opens in new window)A report presenting the joint analyses on influenza vaccine effectiveness and role of influenza on IPD and/or CAP incidence will be provided.
Third Study sites protocols to measure influenza vaccine impact in season. (opens in new window)The study site protocols will be based on the generic impact protocol and include the specificity of each study site conducting impact studies.
Third Report I-MOVE+ ST/Scientific Meetings (opens in new window)Report I-MOVE+ ST/Scientific Meetings
First season Study sites protocols to measure influenza vaccine impact in season. (opens in new window)The study site protocols will be based on the generic impact protocol and include the specificity of each study site conducting impact studies.
Third. Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness. (opens in new window)Each season, the study sites will adapt the generic protocol by describing the setting in each of the seasons (e.g. vaccines used, start of vaccination campaign, change in the number of GPs participating in the surveillance network, etc).
Scientific Manuscript WP5 (opens in new window)Depending on the results in task 5.1 and 5.2 the findings will be presented in one or two peer-reviewed publications.
First End of season, pooled influenza vaccine effectiveness estimates report. (opens in new window)The final pooled VE report will include the results of the multicentre case control studies (primary care and hospital studies) and a summary of the studies conducted within WP4 using electronic databases. The report will include the results of the research questions addressed (effect of previous vaccinations, duration of protection).
Written report including a generic cost-effectiveness model (opens in new window)Written report including a generic cost-effectiveness model which can be used among the participating countries; Depending on the results in task 5.1 and 5.2 the findings will be presented in one or two peer-reviewed publications, Month 24. As the deliverables of this work package are heavily dependent on the availability of data we want to state that we will try to include as many countries participating in WP2,3 and 4 as possible. Scotland, the Netherlands, Germany and Finland will contribute.
Third End of season, pooled influenza vaccine effectiveness estimates report. (opens in new window)The final pooled VE report will include the results of the multicentre case control studies (primary care and hospital studies) and a summary of the studies conducted within WP4 using electronic databases. The report will include the results of the research questions addressed (effect of previous vaccinations, duration of protection).
Second Report I-MOVE+ ST/Scientific Meetings (opens in new window)Report I-MOVE+ ST/Scientific Meetings
Generic protocols for effectiveness and impact studies of pneumococcal vaccines (opens in new window)The generic protocols will include a description of study designs, the setting(s), the plan of analysis for study site estimates and for pooled estimates, the minimum set of variables to be collected, sample size. They will specify the parts that each study site will have to document when writing the study site protocol. Generic protocols will detail the methods used and the plan of analysis to answer to specific research questions such as the duration of protection, magnitude of replacement etc.
First Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness. (opens in new window)This will include additional information obtained through deliverables D4.1. The study sites will adapt the generic influenza protocol by describing the study design(s), the outcomes, the settings (GP, hospital based), the types of vaccines, the plan of analysis, the variables that will be included in the analysis and how these are obtained, how previous vaccinations are accounted for etc. The plan of analysis will describe how to measure vaccine effectiveness (direct effect) in the elderly population, including adjustment for confounders by covariates or (if possible) imputations.
Scientific manuscript WP4 (opens in new window)Scientific manuscript that presents 1) the results from the comparison of influenza VE estimates using different methods on the same database 2) Effect of previous influenza vaccinations on current influenza VE.
Training material available. (opens in new window)A set of training material will be available on the website addressing methodological issues of studies measuring the effects of the influenza vaccine and data analysis. The training material will include presentations, case studies and programmes for data analysis.
Report with description of influenza and pneumococcal outcomes in each database. (opens in new window)The report includes A) Descriptions of influenza outcomes in each database, including detailed information on methods used for detection and subtyping in each county. Description of information on vaccines (product name, repeated vaccination eg) and level of information on risk factors and confounders. B) The comparability of the databases is explored in order to identify a common level of detail of information in the databases, which allows register-based studies across countries.
Second Study sites protocols to measure influenza vaccine impact in season. (opens in new window)The study site protocols will be based on the generic impact protocol and include the specificity of each study site conducting impact studies.
Scientific communication (opens in new window)Summarise lessons learned as regards the use of electronic databases.
Second. Study sites protocols and clearance from Ethical Committee to measure influenza vaccine effectiveness. (opens in new window)Each season the study sites will adapt the generic protocol by describing the setting in each of the seasons eg vaccines used start of vaccination campaign change in the number of GPs participating in the surveillance network etc
An I-MOVE+ website will be available with three levels of access: restricted to study sites conducting studies and ECDC, restricted to I-MOVE+ partners, and open to public. Study sites will exchange results using the restricted website area. In this restricted area, sites will update on a regular basis the number of individuals recruited in the studies. Preliminary results will be shared among relevant study sites during periodic videoconferences. The website will include a library of documents (protocols, articles, training material, videoconference minutes etc).
Publications
Author(s):
A.M. Vilcu, C. Souty, V. Enouf, L. Capai, C. Turbelin, S. Masse, S. Behillil, M. Valette, C. Guerrisi, L. Rossignol, T. Blanchon, B. Lina, T. Hanslik, A. Falchi
Published in:
Clinical Microbiology and Infection, 2017, ISSN 1198-743X
Publisher:
Blackwell Publishing Inc.
DOI:
10.1016/j.cmi.2017.09.003
Author(s):
Marc Rondy, Amparo Larrauri, Itziar Casado, Valeria Alfonsi, Daniela Pitigoi, Odile Launay, Ritva K Syrjänen, Giedre Gefenaite, Ausenda Machado, Vesna Višekruna Vučina, Judith Krisztina Horváth, Iwona Paradowska-Stankiewicz, Sierk D Marbus, Alin Gherasim, Jorge Alberto Díaz-González, Caterina Rizzo, Alina E Ivanciuc, Florence Galtier, Niina Ikonen, Aukse Mickiene, Veronica Gomez, Sanja Kure
Published in:
Eurosurveillance, Issue 22/30, 2017, ISSN 1025-496X
Publisher:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2017.22.30.30580
Author(s):
Dominic Thorrington, Edwin van Leeuwen, Mary Ramsay, Richard Pebody, Marc Baguelin
Published in:
BMC Medicine, Issue 15/1, 2017, ISSN 1741-7015
Publisher:
BioMed Central
DOI:
10.1186/s12916-017-0932-3
Author(s):
Alin Gherasim, Iván Martínez-Baz, Jesús Castilla, Francisco Pozo, Amparo Larrauri
Published in:
PLOS ONE, Issue 12/6, 2017, Page(s) e0179160, ISSN 1932-6203
Publisher:
Public Library of Science
DOI:
10.1371/journal.pone.0179160
Author(s):
Cécile Souty, Ana-Maria Vilcu, Lisandru Capai, Sylvie van der Werf, Martine Valette, Thierry Blanchon, Bruno Lina, Sylvie Behillil, Thomas Hanslik, Alessandra Falchi
Published in:
Journal of Clinical Virology, Issue 95, 2017, Page(s) 1-4, ISSN 1386-6532
Publisher:
Elsevier BV
DOI:
10.1016/j.jcv.2017.08.002
Author(s):
Marc Rondy, Odile Launay, Jesus Castilla, Simona Costanzo, Joan Puig-Barberà, Giedre Gefenaite, Amparo Larrauri, Caterina Rizzo, Daniela Pitigoi, Ritva K. Syrjänen, Ausenda Machado, Sanja Kurečić Filipović, Judit Krisztina Horváth, Iwona Paradowska-Stankiewicz, Sierk Marbus, Alain Moren
Published in:
Vaccine, Issue 35/34, 2017, Page(s) 4298-4306, ISSN 0264-410X
Publisher:
Elsevier BV
DOI:
10.1016/j.vaccine.2017.06.088
Author(s):
Esther Kissling, Marta Valenciano, Francisco Pozo, Ana-Maria Vilcu, Annicka Reuss, Caterina Rizzo, Amparo Larrauri, Judit Krisztina Horváth, Mia Brytting, Lisa Domegan, Monika Korczyńska, Adam Meijer, Ausenda Machado, Alina Ivanciuc, Vesna Višekruna Vučina, Sylvie van der Werf, Brunhilde Schweiger, Antonino Bella, Alin Gherasim, Annamária Ferenczi, Katherina Zakikhany, Joan O′Donnell, Iwona
Published in:
Influenza and Other Respiratory Viruses, 2017, ISSN 1750-2640
Publisher:
Blackwell Publishing Inc.
DOI:
10.1111/irv.12520
Author(s):
Marc Rondy, Esther Kissling, Hanne-Dorthe Emborg, Alin Gherasim, Richard Pebody, Ramona Trebbien, Francisco Pozo, Amparo Larrauri, Jim McMenamin, Marta Valenciano
Published in:
Eurosurveillance, Issue 23/9, 2018, ISSN 1560-7917
Publisher:
Eurosurveillance
DOI:
10.2807/1560-7917.ES.2018.23.9.18-00086
Author(s):
Marc Rondy, Alin Gherasim, Itziar Casado, Odile Launay, Caterina Rizzo, Daniela Pitigoi, Aukse Mickiene, Sierk D Marbus, Ausenda Machado, Ritva K Syrjänen, Iva Pem-Novose, Judith Krisztina Horváth, Amparo Larrauri, Jesús Castilla, Philippe Vanhems, Valeria Alfonsi, Alina E Ivanciuc, Monika Kuliese, Rianne van Gageldonk-Lafeber, Veronica Gomez, Niina Ikonen, Zvjezdana Lovric, Annamária Ferenczi
Published in:
Eurosurveillance, Issue 22/41, 2017, ISSN 1560-7917
Publisher:
Eurosurveillance
DOI:
10.2807/1560-7917.ES.2017.22.41.17-00645
Author(s):
Marta Valenciano, Esther Kissling, Amparo Larrauri, Baltazar Nunes, Daniela Pitigoi, Joan O'Donnell, Annicka Reuss, Judit Krisztina Horváth, Iwona Paradowska-Stankiewicz, Caterina Rizzo, Alessandra Falchi, Isabelle Daviaud, Mia Brytting, Adam Meijer, Bernard Kaic, Alin Gherasim, Ausenda Machado, Alina Ivanciuc, Lisa Domegan, Brunhilde Schweiger, Annamária Ferenczi, Monika Korczyńska, Antonino B
Published in:
Influenza and Other Respiratory Viruses, Issue 12/5, 2018, Page(s) 567-581, ISSN 1750-2640
Publisher:
Blackwell Publishing Inc.
DOI:
10.1111/irv.12562
Author(s):
Dominic Thorrington, Leo van Rossum, Mirjam Knol, Hester de Melker, Hans Rümke, Eelko Hak, Albert Jan van Hoek
Published in:
PLOS ONE, Issue 13/2, 2018, Page(s) e0192640, ISSN 1932-6203
Publisher:
Public Library of Science
DOI:
10.1371/journal.pone.0192640
Author(s):
Omar Okasha, Hanna Rinta-Kokko, Arto A Palmu, Esa Ruokokoski, Jukka Jokinen, J Pekka Nuorti
Published in:
Thorax, Issue 73/3, 2018, Page(s) 262-269, ISSN 0040-6376
Publisher:
BMJ Publishing Group
DOI:
10.1136/thoraxjnl-2017-210440
Author(s):
Germaine Hanquet, Pavla Krizova, Palle Valentiner-Branth, Shamez N Ladhani, J Pekka Nuorti, Agnes Lepoutre, Jolita Mereckiene, Mirjam Knol, Brita A Winje, Pilar Ciruela, Maria Ordobas, Marcela Guevara, Eisin McDonald, Eva Morfeldt, Jana Kozakova, Hans-Christian Slotved, Norman K Fry, Hanna Rinta-Kokko, Emmanuelle Varon, Mary Corcoran, Arie van der Ende, Didrik F Vestrheim, Carmen Munoz-Almagro, Pe
Published in:
Thorax, 2018, Page(s) thoraxjnl-2018-211767, ISSN 0040-6376
Publisher:
BMJ Publishing Group
DOI:
10.1136/thoraxjnl-2018-211767
Author(s):
Itziar Casado, Ángela Domínguez, Diana Toledo, Judith Chamorro, Jenaro Astray, Mikel Egurrola, María Amelia Fernández-Sierra, Vicente Martín, María Morales-Suárez-Varela, Pere Godoy, Jesús Castilla
Published in:
Canadian Medical Association Journal, Issue 190/1, 2018, Page(s) E3-E12, ISSN 0820-3946
Publisher:
Canadian Medical Association/Association Medical Canadienne
DOI:
10.1503/cmaj.170910
Author(s):
Jesús Castilla, Ana Navascués, Itziar Casado, Alejandra Pérez-García, Aitziber Aguinaga, Guillermo Ezpeleta, Francisco Pozo, Carmen Ezpeleta, Iván Martínez-Baz
Published in:
Eurosurveillance, Issue 23/7, 2018, ISSN 1560-7917
Publisher:
Eurosurveillance
DOI:
10.2807/1560-7917.es.2018.23.7.18-00057
Author(s):
Richard G Pebody, Mary A Sinnathamby, Fiona Warburton, Nick Andrews, Nicola L Boddington, Hongxin Zhao, Ivelina Yonova, Joanna Ellis, Elise Tessier, Matthew Donati, Alex J Elliot, Helen E Hughes, Sameera Pathirannehelage, Rachel Byford, Gillian E Smith, Simon de Lusignan, Maria Zambon
Published in:
Eurosurveillance, Issue 23/25, 2018, ISSN 1560-7917
Publisher:
Eurosurveillance
DOI:
10.2807/1560-7917.es.2018.23.25.1700496
Author(s):
Ana Navascués, Itziar Casado, Alejandra Pérez-García, Aitziber Aguinaga, Iván Martínez-Baz, Yugo Floristán, Carmen Ezpeleta, Jesús Castilla
Published in:
Emerging Infectious Diseases, Issue 24/7, 2018, Page(s) 1331-1334, ISSN 1080-6040
Publisher:
US National Center for Infectious Diseases
DOI:
10.3201/eid2407.180162
Author(s):
Adam Meijer, Corien M Swaan, Martin Voerknecht, Edin Jusic, Sharon van den Brink, Lisa A Wijsman, Bettie CG Voordouw, Gé A Donker, Jacqueline Sleven, Wendelien W Dorigo-Zetsma, Sanela Svraka, Michiel van Boven, Manon R Haverkate, Aura Timen, Jaap T van Dissel, Marion PG Koopmans, Theo M Bestebroer, Ron AM Fouchier
Published in:
Eurosurveillance, Issue 23/15, 2018, ISSN 1560-7917
Publisher:
Eurosurveillance
DOI:
10.2807/1560-7917.es.2018.23.15.18-00160
Author(s):
Irina Kislaya, Ana Paula Rodrigues, Mafalda Sousa-Uva, Verónica Gómez, Paulo Gonçalves, Filipe Froes, Baltazar Nunes
Published in:
PLOS ONE, Issue 14/1, 2019, Page(s) e0209428, ISSN 1932-6203
Publisher:
Public Library of Science
DOI:
10.1371/journal.pone.0209428
Author(s):
Esther Kissling, Marc Rondy
Published in:
Eurosurveillance, Issue 22/7, 2017, ISSN 1025-496X
Publisher:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2017.22.7.30464
Author(s):
Maria-Pia Hergens, Ulrike Baum, Mia Brytting, Niina Ikonen, Anu Haveri, Åsa Wiman, Hanna Nohynek, Åke Örtqvist
Published in:
Eurosurveillance, Issue 22/8, 2017, ISSN 1025-496X
Publisher:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2017.22.8.30469
Author(s):
Jesús Castilla, Ana Navascués, Itziar Casado, Jorge Díaz-González, Alejandra Pérez-García, Leticia Fernandino, Iván Martínez-Baz, Aitziber Aguinaga, Francisco Pozo, Carmen Ezpeleta
Published in:
Eurosurveillance, Issue 22/7, 2017, ISSN 1025-496X
Publisher:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2017.22.7.30465
Author(s):
Iván Martínez-Baz, Itziar Casado, Ana Navascués, Jorge Díaz-González, Aitziber Aguinaga, Laura Barrado, Josu Delfrade, Carmen Ezpeleta, Jesús Castilla
Published in:
The Journal of Infectious Diseases, 2017, ISSN 0022-1899
Publisher:
University of Chicago Press
DOI:
10.1093/infdis/jix055
Author(s):
Hanne Dorthe Emborg, Tyra Grove Krause, Lene Nielsen, Marianne Kragh Thomsen, Claus Bohn Christiansen, Marianne Nielsine Skov, Xiaohui Chen Nielsen, Lenette Sandborg Weinreich, Thea Kølsen Fischer, Jesper Rønn, Ramona Trebbien
Published in:
Eurosurveillance, Issue 21/14, 2016, ISSN 1025-496X
Publisher:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2016.21.14.30189
Author(s):
Richard Pebody, Fiona Warburton, Joanna Ellis, Nick Andrews, Alison Potts, Simon Cottrell, Jillian Johnston, Arlene Reynolds, Rory Gunson, Catherine Thompson, Monica Galiano, Chris Robertson, David Mullett, Naomh Gallagher, Mary Sinnathamby, Ivelina Yonova, Catherine Moore, Jim McMenamin, Simon de Lusignan, Maria Zambon
Published in:
Eurosurveillance, Issue 21/13, 2016, ISSN 1025-496X
Publisher:
Centre Europeen pour la Surveillance Epidemiologique du SIDA
DOI:
10.2807/1560-7917.ES.2016.21.13.30179
Author(s):
Jim Mc Menamin
Published in:
The Parliament Magazine, 2017
Publisher:
DODS
Author(s):
Gómez, Verónica; Guiomar, Raquel; Rodrigues, Ana Paula; Pechirra, Pedro; Conde, Patrícia; Cristóvão, Paula; Costa, Inês; Nunes, Baltazar; Machado, Ausenda
Published in:
Issue 2, 2016
Publisher:
National Health Institute Doutor Ricardo Jorge
Author(s):
Jim McMenamin
Published in:
The Parliament Magazine, Issue Issue 432/18 April 2016, 2016
Publisher:
DODS
Author(s):
Rodrigues, Ana Paula; Pechirra, Pedro; Guiomar, Raquel; Conde, Patrícia; Gomez, Verónica; Nunes, Baltazar; Machado, Ausenda
Published in:
Issue 1, 2016
Publisher:
Instituto Nacional de Saúde Doutor Ricardo Jorge, IP
Searching for OpenAIRE data...
There was an error trying to search data from OpenAIRE
No results available